Financial
Latest full-year results from official filings.
FY2025 revenue $44.33bn (+5.7%); operating margin 18.2%; net income $6.52bn.
Balance sheet figures not captured from release.
- Official results release · Abbott · 31 Dec 2025
Abbott: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Mar 2026: Abbott completed its acquisition of Exact Sciences, adding cancer screening and diagnostics such as Cologuard; the acquired business was later the subject of a cyber incident (see Cyber & information governance).
- Abbott completes acquisition of Exact Sciences · Abbott · 23 Mar 2026
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
Jul 2026: Abbott confirmed unauthorised access to a limited number of legacy Exact Sciences systems in its Cancer Diagnostics business and investigated a potential incident on its LabCentral portal; hackers claimed large data theft, which Abbott has not confirmed. NHS DSPT status not yet checked.
- Abbott Laboratories probes two cyber incidents amid extortion claims · BleepingComputer · 17 Jul 2026
- Abbott statement on cyber incident in Cancer Diagnostics business · Abbott · 1 Jul 2026
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Dec 2025: millions of FreeStyle Libre 3 and Libre 3 Plus glucose sensors were recalled over faulty low readings, which the FDA linked to seven deaths and hundreds of serious injuries worldwide.
- Millions of Abbott glucose sensors recalled after faulty readings linked to deaths · HealthDay · 4 Dec 2025
- FDA: Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors recalled after seven deaths, 860 injuries · KTVU (FOX) · 1 Dec 2025
Contract performance
Contract delivery, go-lives, terminations and disputes.
No notable NHS contracts, troubled implementations, disputes or terminations involving Abbott found in HSH's search of the last 24 months.